Abstract:Objectives: Glioblastoma is one of the most frequent primitive brain tumors. Patients who experience tumor relapse after surgery and concomitant radiochemotherapy have a dismal prognosis. The objective of this study is to analyze efficacy data in terms of overall survival (OS) and progression- free survival (PFS) following combination therapy with bevacizumab (BVZ) and irinotecan among patients with relapsed glioblastoma. Safety data will also be reviewed and all results will be compared with data of the liter… Show more
“…A phase ΙΙΙ trial on the combination of lomustine and bevacizumab is ongoing by EORTC (study 26101, NCT01290939). Another single-center study from 2016, the SV1-study, also support our findings with similar results where median PFS was 26 weeks and median OS was 28 weeks (20).…”
Results from this retrospective study are comparable with earlier phase-II studies and motivate randomized trials of bevacizumab-based treatment in the second-line setting.
“…A phase ΙΙΙ trial on the combination of lomustine and bevacizumab is ongoing by EORTC (study 26101, NCT01290939). Another single-center study from 2016, the SV1-study, also support our findings with similar results where median PFS was 26 weeks and median OS was 28 weeks (20).…”
Results from this retrospective study are comparable with earlier phase-II studies and motivate randomized trials of bevacizumab-based treatment in the second-line setting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.